Evidence-based considerations for NAMs
We are delighted to share a wonderful commentary by Dr. Eckhard von Keutz, published in Regulatory Toxicology and Pharmacology in June 2025. In this commentary, Dr. Eckhard von Keutz makes the case for the accelerated—yet evidence-based—adoption of human-relevant New Approach Methodologies (NAMs) in preclinical drug testing.
Certain in vitro tools are ready for evidence-based considerations for specific contexts of use such as drug-induced liver injury, a common blind spot in drug safety. Supported by data, mechanism-informative NAMs can be a powerful lens for predicting DILI. Dr. von Keutz, thank you for highlighting the path forward. The time to act is now! Lena Biosciences is proud to be a part of it.
Certain in vitro tools are ready for evidence-based considerations for specific contexts of use such as drug-induced liver injury, a common blind spot in drug safety. Supported by data, mechanism-informative NAMs can be a powerful lens for predicting DILI. Dr. von Keutz, thank you for highlighting the path forward. The time to act is now! Lena Biosciences is proud to be a part of it.
June 25, 2025
